{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:31:01Z","timestamp":1784212261423,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015613","name":"Centre hospitalier r\u00e9gional universitaire de Lille","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medical Genetics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejmg.2025.105012","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T02:45:56Z","timestamp":1742697956000},"page":"105012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Lack of behavioural improvement with sirolimus in a patient with MTOR-related macrocephaly with pigmentary mosaicism: A new case report"],"prefix":"10.1016","volume":"75","author":[{"given":"Bertille","family":"Bonniaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coline","family":"Cormier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Racine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Espitalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Malbranche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e9la\u00efde","family":"Rega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9o","family":"Gaumet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kuentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Vabres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Thauvin-Robinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bardou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9770-444X","authenticated-orcid":false,"given":"Laurence","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Delanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmg.2025.105012_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ridd.2021.104029","volume":"116","author":"Adrien","year":"2021","journal-title":"Res. Dev. Disabil."},{"key":"10.1016\/j.ejmg.2025.105012_bib2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent advances and limitations of mTOR inhibitors in the treatment of cancer","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmg.2025.105012_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2017.05.001","article-title":"Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors","volume":"57","author":"Antonuzzo","year":"2017","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"10.1016\/j.ejmg.2025.105012_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neurol.2022.12.007","article-title":"mTOR-therapy and targeted treatment opportunities in mTOR-related epilepsies associated with cortical malformations","volume":"179","author":"Auvin","year":"2023","journal-title":"Rev. Neurol. (Paris)"},{"issue":"9869","key":"10.1016\/j.ejmg.2025.105012_bib5","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet Lond Engl"},{"issue":"7","key":"10.1016\/j.ejmg.2025.105012_bib6","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)."},{"issue":"8","key":"10.1016\/j.ejmg.2025.105012_bib7","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41436-021-01161-6","article-title":"Clinical spectrum of MTOR-related hypomelanosis of Ito with neurodevelopmental abnormalities","volume":"23","author":"Carmignac","year":"2021","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ejmg.2025.105012_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050008","article-title":"Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma","volume":"5","author":"Cloughesy","year":"2008","journal-title":"PLoS Med."},{"issue":"8","key":"10.1016\/j.ejmg.2025.105012_bib9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1788","article-title":"Reversal of learning deficits in a Tsc2+\/- mouse model of tuberous sclerosis","volume":"14","author":"Ehninger","year":"2008","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.ejmg.2025.105012_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/cge.14511","article-title":"Allelic heterogeneity in a patient with postzygotic MTOR-related hypomelanosis of Ito with neurodevelopmental abnormalities","volume":"105","author":"Engel","year":"2024","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ejmg.2025.105012_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102886","article-title":"Mechanisms of resistance to mTOR inhibitors","volume":"147","author":"Formisano","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.ejmg.2025.105012_bib12","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1177\/0883073812449904","article-title":"Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"28","author":"Franz","year":"2013","journal-title":"J. Child Neurol."},{"issue":"10056","key":"10.1016\/j.ejmg.2025.105012_bib13","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Efficacy and safety of everolimus for epilepsy associated with tuberous sclerosis complex (EXIST-3): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"Franz","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.ejmg.2025.105012_bib14","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"10.1016\/j.ejmg.2025.105012_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2020.104036","article-title":"Compassionate use of everolimus for refractory epilepsy in a patient with MTOR mosaic mutation","volume":"63","author":"Hadouiri","year":"2020","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.ejmg.2025.105012_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1352803","article-title":"Drug repurposing for rare diseases: progress and opportunities for the rare disease community","volume":"11","author":"Jonker","year":"2024","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.ejmg.2025.105012_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41379-021-00896-6","article-title":"Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney","volume":"35","author":"Kapur","year":"2022","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.ejmg.2025.105012_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/acn3.51505","article-title":"Sirolimus for epileptic seizures associated with focal cortical dysplasia type II","volume":"9","author":"Kato","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"10.1016\/j.ejmg.2025.105012_bib19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.ejmg.2025.105012_bib20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/ng.2329","article-title":"De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly","volume":"44","author":"Lee","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmg.2025.105012_bib21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nm.3824","article-title":"Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy","volume":"21","author":"Lim","year":"2015","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.ejmg.2025.105012_bib23","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamaneurol.2016.0363","article-title":"Association of MTOR mutations with developmental brain disorders, including megalencephaly, focal cortical dysplasia, and pigmentary mosaicism","volume":"73","author":"Mirzaa","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejmg.2025.105012_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ana.24444","article-title":"Somatic mutations in the MTOR gene cause focal cortical dysplasia type IIb","volume":"78","author":"Nakashima","year":"2015","journal-title":"Ann. Neurol."},{"issue":"19","key":"10.1016\/j.ejmg.2025.105012_bib25","first-page":"e1814","article-title":"Sirolimus use and neurodevelopmental outcome in children with tuberous sclerosis complex: an observational study","volume":"93","author":"Overwater","year":"2019","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ejmg.2025.105012_bib26","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41436-018-0297-9","article-title":"Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum","volume":"21","author":"Parker","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ejmg.2025.105012_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pediatrneurol.2020.10.013","article-title":"Sirolimus treatment in Sturge-Weber syndrome","volume":"115","author":"Sebold","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ejmg.2025.105012_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4137\/JGE.S12583","article-title":"Exome sequencing reveals de novo germline mutation of the mammalian target of rapamycin (MTOR) in a patient with megalencephaly and intractable seizures","volume":"2","author":"Smith","year":"2013","journal-title":"J Genomes Exomes"},{"issue":"5","key":"10.1016\/j.ejmg.2025.105012_bib29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","article-title":"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmg.2025.105012_bib31","article-title":"Impact of mTOR inhibitors on neurobehavioral symptoms in children with tuberous sclerosis complex","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.ejmg.2025.105012_bib32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/0883073818813238","article-title":"mTOR inhibitors as a new therapeutic strategy in treatment-resistant epilepsy in hemimegalencephaly: a case report","volume":"34","author":"Xu","year":"2019","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.ejmg.2025.105012_bib33","unstructured":"ClinGen: https:\/\/search.clinicalgenome.org\/kb\/gene-validity\/CGGV:assertion_92ce0145-031d-41c4-8b74-0f9411629b64-2021-07-29T213256.506Z?page=1&size=25&search=."},{"key":"10.1016\/j.ejmg.2025.105012_bib34","unstructured":"ClinVar: https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/520633\/."},{"key":"10.1016\/j.ejmg.2025.105012_bib35","unstructured":"gnomAD v4-1: https:\/\/gnomad.broadinstitute.org\/news\/2024-04-gnomad-v4-1\/."}],"container-title":["European Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721225000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721225000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T23:33:09Z","timestamp":1762558389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769721225000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":33,"alternative-id":["S1769721225000199"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmg.2025.105012","relation":{},"ISSN":["1769-7212"],"issn-type":[{"value":"1769-7212","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of behavioural improvement with sirolimus in a patient with MTOR-related macrocephaly with pigmentary mosaicism: A new case report","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medical Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmg.2025.105012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105012"}}